Baxter secures $2.2 billion credit agreement
- Investing.com
- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Baxter International Inc (BAX)
Baxter International Inc stock price live, this page displays NYSE BAX stock exchange data. View the BAX premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Baxter International Inc real time stock price chart below.
What Is the Baxter International Inc Stock Price Today?
The Baxter International Inc stock price today is 29.80.
What Is the Stock Symbol for Baxter International Inc?
The stock symbol for Baxter International Inc is "BAX."
What Stock Exchange Does Baxter International Inc Trade On?
Baxter International Inc is listed and trades on the NYSE stock exchange.
Is Baxter International Inc a Good Stock to Buy?
Determining whether Baxter International Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the BAX quote. (ISIN: US0718131099)
What Is the Baxter International Inc Stock Price Today?
The Baxter International Inc stock price today is 29.80.
What Is the Stock Symbol for Baxter International Inc?
The stock symbol for Baxter International Inc is "BAX."
What Stock Exchange Does Baxter International Inc Trade On?
Baxter International Inc is listed and trades on the NYSE stock exchange.
Is Baxter International Inc a Good Stock to Buy?
Determining whether Baxter International Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the BAX quote. (ISIN: US0718131099)
29.80
-0.12(-0.40%)
Closed·
After Hours
30.00+0.20(+0.67%)
·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
29.54
30.10
52 wk Range
26.25
40.49
BAX Scorecard
Full Analysis
Net income is expected to grow this year
BAX is not included in our AI-picked strategies. See which stocks are.
Review Strategies
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
29.5430.10
52 wk Range
26.2540.49
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(2.28%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(2.28%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
BAX Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Neutral
Price Target
38.34
Upside
+28.67%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
5 analysts have revised their earnings upwards for the upcoming period
- Baxter Declares Quarterly Dividend
- Investing.com
- Baxter secures $2.2 billion credit agreement
- Investing.com
Baxter International Inc Company Profile
Baxter International Inc., through its subsidiaries, provides a portfolio of healthcare products in the United States. The company operates through three segments: Medical Products and Therapies, Healthcare Systems and Technologies, and Pharmaceuticals. It offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; administrative sets; generic injectable pharmaceuticals; surgical hemostat and sealant products; advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space comprising operating room integration technologies, precision positioning devices, and other accessories. The company also provides specialty injectable pharmaceuticals, inhaled anesthetics, and drug compounding services. Its products are used in hospitals, nursing homes, rehabilitation centers, ambulatory surgery centers, doctors’ offices, kidney dialysis centers, and patients at home under physician supervision. The company sells its products through direct sales force, independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers. It has an agreement with Celerity Pharmaceuticals, LLC to develop acute care generic injectable premix and oncolytic products. The company operates in Eastern Europe, the Middle East, Africa, Latin America, Asia, Western Europe, Canada, Japan, Australia, and New Zealand. Baxter International Inc. was incorporated in 1931 and is headquartered in Deerfield, Illinois.
Baxter International Inc SWOT Analysis
Healthcare Titan | Baxter International, a $17.85B market cap leader in medical supplies, boasts a 55-year dividend streak amid industry shifts |
Analyst Optimism | Barclays reinstates Overweight rating with $39 price target, signaling renewed confidence in Baxter's market outperformance potential |
Financial Resilience | EPS projections show growth from $2.50 in FY2025 to $2.28 in FY2, with analysts predicting a return to profitability despite recent challenges |
Strategic Positioning | Baxter navigates regulatory hurdles and competitive pressures while capitalizing on aging populations and emerging markets for sustained growth |
Baxter International Inc Earnings Call Summary for Q1/2025
- Baxter International beats Q1 2025 expectations with adjusted EPS of $0.55 and revenue of $2.63 billion, surpassing forecasts
- Adjusted operating margin improved to 14.9%, up 260 basis points year-over-year, driven by operational efficiency
- Full-year 2025 guidance remains strong with projected sales growth of 7-8% and adjusted EPS between $2.47 and $2.55
- Stock rose 1.24% post-announcement; company plans inorganic investments and share buyback program
- Anticipated tariffs could impact financials by $60-$70 million in 2025; company focuses on cost containment strategies
Last Updated: 2025/05/01, 15:46
Read Full TranscriptCompare BAX to Peers and Sector
Metrics to compare | BAX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipBAXPeersSector | |
|---|---|---|---|---|
P/E Ratio | −55.2x | 37.5x | −0.5x | |
PEG Ratio | 0.46 | 0.85 | 0.00 | |
Price/Book | 2.2x | 4.5x | 2.6x | |
Price / LTM Sales | 1.4x | 3.6x | 3.0x | |
Upside (Analyst Target) | 19.1% | 17.0% | 51.5% | |
Fair Value Upside | Unlock | −6.5% | 9.4% | Unlock |
Analyst Ratings
6 Buy
11 Hold
1 Sell
Ratings:
18 analysts
Overall Consensus
Neutral
Analysts 12-Month Price Target:
Average 38.34
(+28.67% Upside)
Earnings
Latest Release
May 01, 2025
EPS / Forecast
0.55 / 0.48
Revenue / Forecast
2.63B / 2.59B
FAQ
What Is the Baxter (BAX) Stock Price Today?
The Baxter stock price today is 29.80
What Stock Exchange Does Baxter Trade On?
Baxter is listed and trades on the New York Stock Exchange stock exchange.
What Is the Stock Symbol for Baxter?
The stock symbol for Baxter is "BAX."
Does Baxter Pay Dividends? What’s The Current Dividend Yield?
The Baxter dividend yield is 2.28%.
What Is the Baxter Market Cap?
As of today, Baxter market cap is 15.29B.
What Is Baxter's Earnings Per Share (TTM)?
The Baxter EPS (TTM) is -0.54.
When Is the Next Baxter Earnings Date?
Baxter will release its next earnings report on 23 Jul 2025.
From a Technical Analysis Perspective, Is BAX a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has Baxter Stock Split?
Baxter has split 4 times.
How Many Employees Does Baxter Have?
Baxter has 38000 employees.
What is the current trading status of Baxter (BAX)?
As of 19 Jun 2025, Baxter (BAX) is trading at a price of 29.80, with a previous close of 29.92. The stock has fluctuated within a day range of 29.54 to 30.10, while its 52-week range spans from 26.25 to 40.49.
What Is Baxter (BAX) Price Target According to Analysts?
The average 12-month price target for Baxter is USD38.3425, with a high estimate of USD55 and a low estimate of USD28. 6 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Neutral. The stock has an +28.67% Upside potential.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.